Refine
Has Fulltext
- yes (42)
Is part of the Bibliography
- yes (42)
Year of publication
Document Type
- Journal article (42)
Language
- English (42)
Keywords
- psoriasis (4)
- Merkel cell carcinoma (3)
- immunohistochemistry (3)
- therapy (3)
- COVID-19 (2)
- Germany (2)
- PD-L1 (2)
- T cells (2)
- dermatology (2)
- inflammation (2)
- melanoma (2)
- B cells (1)
- B-cell lymphoma (1)
- B-cells (1)
- B7-H1 Antigen (1)
- CD10 (1)
- CD274 (1)
- CD30 (1)
- CD8(+) (1)
- CTLA-4 Antigen (1)
- Clinical trials (1)
- Crohn disease (1)
- Cutaneous lymphoma (1)
- Cutaneous metastatic Crohn’s disease (1)
- Cx43 (1)
- Drug Therapy, Combination (1)
- EBER in situ hybridization (1)
- ERBB receptors (1)
- EVER1 (1)
- EVER2 (1)
- Epigenetic regulation (1)
- FoxO3 (1)
- HDAC (1)
- Histone deacetylase (1)
- Human papillomavirus (1)
- IFN (1)
- Immune-related adverse event (1)
- Ipilimumab (1)
- JAK2 (1)
- Kaposi sarcoma (1)
- Kerinokeratosis papulosa (1)
- LRIG1 (1)
- LSD1 (1)
- Lysine-specific methylase (1)
- Melanoma (1)
- Minimal change disease (1)
- Molecular imaging (1)
- Mycobacterium marinum (1)
- Nfatc1 (1)
- Nivolumab (1)
- PD-1 (1)
- PEComa (1)
- PRAME (1)
- Positron emission tomography (1)
- Programmed Cell Death 1 Receptor (1)
- RNA probe (1)
- S2k guidelines (1)
- SARS-CoV-2 (1)
- Skin (1)
- Skin Neoplasms (1)
- Somatostatin receptor expression (1)
- T-antigens (1)
- TP53 (1)
- TRRAP (1)
- Th17 (1)
- Tregs (1)
- Tubulin (1)
- United States (1)
- Waxy papulosis of childhood (1)
- acitretin (1)
- adverse event (1)
- allergies (1)
- allergy (1)
- aluminum granuloma (1)
- antitumor immunity (1)
- autoimmune disease (1)
- autoimmune diseases (1)
- avelumab (1)
- biologics (1)
- biomarker (1)
- breast cancer (1)
- bullous pemphigoid (1)
- cancer microenvironment (1)
- cell membranes (1)
- cell rich blue nevus (1)
- cell staining (1)
- chemokine (1)
- cicatricial pemphigoid (1)
- classification (1)
- common blue nevus (1)
- comorbid diseases (1)
- cutaneous PEComa (1)
- cutaneous T-cell-lymphoma (1)
- cutaneous adverse events (1)
- cutaneous angiosarcoma (1)
- cutaneous lupus erythematosus (1)
- cutaneous lymphomas (1)
- diagnosis (1)
- differential gene expression (1)
- disease severity (1)
- drug therapy (1)
- drug-induced liver injury (DILI) (1)
- endemic pemphigus foliaceus (1)
- environmental factors (1)
- eosinophils (1)
- experience (1)
- fatty liver disease (1)
- genetic association (1)
- health economics (1)
- health insurance (1)
- health-care costs (1)
- hemangioma (1)
- histologic findings (1)
- immune cell infiltration (1)
- immunology (1)
- immunotherapy (1)
- improvement (1)
- indirect costs (1)
- inpatients (1)
- interferon-\(\beta\) (1)
- interleukins (1)
- ipilimumab (1)
- keratinocytes (1)
- laminin 332 (1)
- large cell transformation (1)
- leg cramps (1)
- lesions (1)
- lichen planus (1)
- life (1)
- long-term outcome (1)
- lung cancer (1)
- lymphocytes (1)
- lymphoid hyperplasia (1)
- melanin (1)
- melanocytes (1)
- melanocytic markers (1)
- melanoma cells (1)
- melanomas (1)
- membrane proteins (1)
- mepacrine (1)
- metastatic (1)
- methylation (1)
- moderate (1)
- mouse model (1)
- mucous membrane pemphigoid (1)
- multicenter (1)
- multiple sclerosis (1)
- mycosis fungoides (1)
- nivolumab (1)
- oesophagogastroduodenoscopy (1)
- orofacial granulomatosis (1)
- outpatients (1)
- over-the-counter drugs (1)
- p53 (1)
- panel sequencing (1)
- patient preferences (1)
- pemphigus foliaceus (1)
- pemphigus vulgaris (1)
- perivascular epitheloid cell tumour (1)
- pityriasis rubra pilaris (1)
- plaque-type psoriasis (1)
- polymavirus (1)
- primary cutaneous follicular B-cell lymphoma (1)
- pseudolymphoma (1)
- pustular exanthema (1)
- quinacrine (1)
- quinine (1)
- resistance (1)
- responses (1)
- review (1)
- rhabdoid differentiation (1)
- rhabdoid melanoma (1)
- satellitosis (1)
- skin (1)
- skin carcinogenesis (1)
- skin reactions (1)
- smoking (1)
- suppression (1)
- surgical and invasive medical procedures (1)
- survival (1)
- systemic sclerosis (1)
- targeted sequencing (1)
- tertiary lymphoid structures (1)
- transcription factors (1)
- treatment options (1)
- tumour immunology (1)
- utaneous adverse events (1)
- uveal melanoma (1)
- vesicles (1)
- virus (1)
Institute
- Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie (42)
- Medizinische Klinik und Poliklinik II (6)
- Pathologisches Institut (6)
- Comprehensive Cancer Center Mainfranken (2)
- Institut für Klinische Epidemiologie und Biometrie (2)
- Institut für Virologie und Immunbiologie (2)
- Kinderklinik und Poliklinik (2)
- Theodor-Boveri-Institut für Biowissenschaften (2)
- Frauenklinik und Poliklinik (1)
- Institut für Humangenetik (1)
Sonstige beteiligte Institutionen
Background: Primary cutaneous follicular B-cell lymphoma (PCFBCL) represents an indolent subtype of Non-Hodgkin’s lymphomas, being clinically characterized by slowly growing tumors of the skin and common cutaneous relapses, while only exhibiting a low propensity for systemic dissemination or fatal outcome. Up to now, only few studies have investigated underlying molecular alterations of PCFBCL with respect to somatic mutations. Objectives: Our aim was to gain deeper insight into the pathogenesis of PCFBCL and to delineate discriminatory molecular features of this lymphoma subtype. Methods: We performed hybridization-based panel sequencing of 40 lymphoma-associated genes of 10 cases of well-characterized PCFBCL. In addition, we included two further ambiguous cases of atypical B-cell-rich lymphoid infiltrate/B-cell lymphoma of the skin for which definite subtype attribution had not been possible by routine investigations. Results: In 10 out of 12 analyzed cases, we identified genetic alterations within 15 of the selected 40 target genes. The most frequently detected alterations in PCFBCL affected the TNFRSF14, CREBBP, STAT6 and TP53 genes. Our analysis unrevealed novel mutations of the BCL2 gene in PCFBCL. All patients exhibited an indolent clinical course. Both the included arbitrary cases of atypical B-cell-rich cutaneous infiltrates showed somatic mutations within the FAS gene. As these mutations have previously been designated as subtype-specific recurrent alterations in primary cutaneous marginal zone lymphoma (PCMZL), we finally favored the diagnosis of PCMZL in these two cases based on these molecular findings. Conclusions: To conclude, our molecular data support that PCFBCL shows distinct somatic mutations which may aid to differentiate PCFBCL from pseudo-lymphoma as well as from other indolent and aggressive cutaneous B-cell lymphomas. While the detected genetic alterations of PCFBCL did not turn out to harbor any prognostic value in our cohort, our molecular data may add adjunctive discriminatory features for diagnostic purposes on a molecular level.
Elucidating the mechanism of action of domatinostat (4SC-202) in cutaneous T cell lymphoma cells
(2019)
Background
Targeting epigenetic modifiers is effective in cutaneous T cell lymphoma (CTCL). However, there is a need for further improvement of this therapeutic approach. Here, we compared the mode of action of romidepsin (FK228), an established class I histone deacetylase inhibitor, and domatinostat (4SC-202), a novel inhibitor of class I HDACs, which has been reported to also target the lysine-specific histone demethylase 1A (LSD1).
Methods
We performed MTS assays and flow cytometric analyses of propidium iodide or annexin V-stained cells to assess drug impact on cellular proliferation, cell cycle distribution, and survival. Histone acetylation and methylation as well as caspase activation was analyzed by immunoblot. Gene expression analysis was performed using NanosString technology. Knockdown and knockout of LSD1 was achieved with shRNA and CRISPR/Cas9, respectively, while the CRISPR/Cas9 synergistic activation mediator system was used to induce expression of endogenous HDACs and LSD1. Furthermore, time-lapse fluorescence microscopy and an in vitro tubulin polymerization assay were applied.
Results
While FK228 as well as 4SC-202 potently induced cell death in six different CTCL cell lines, only in the case of 4SC-202 death was preceded by an accumulation of cells in the G2/M phase of the cell cycle. Surprisingly, apoptosis and accumulation of cells with double DNA content occurred already at 4SC-202 concentrations hardly affecting histone acetylation and methylation, and provoking significantly less changes in gene expression compared to biologically equivalent doses of FK228. Indeed, we provide evidence that the 4SC-202-induced G2/M arrest in CTCL cells is independent of de novo transcription. Furthermore, neither enforced expression of HDAC1 nor knockdown or knockout of LSD1 affected the 4SC-202-induced effects. Since time-lapse microscopy revealed that 4SC-202 could affect mitotic spindle formation, we performed an in vitro tubulin polymerization assay revealing that 4SC-202 can directly inhibit microtubule formation.
Conclusions
We demonstrate that 4SC-202, a drug currently tested in clinical trials, effectively inhibits growth of CTCL cells. The anti-cancer cell activity of 4SC-202 is however not limited to LSD1-inhibition, modulation of histone modifications, and consecutive alteration of gene expression. Indeed, the compound is also a potent microtubule-destabilizing agent.